FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
Status:
Unknown status
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus
idarubicin with granulocyte-colony stimulating factor priming for patients with resistant
acute myeloid leukemia other than acute promyelocytic leukemia